A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients
Background and Objectives
The thrombin inhibitor dabigatran is administered as the prodrug dabigatran etexilate, which is a substrate of esterases and P-glycoprotein (P-gp). Dabigatran is eliminated via renal excretion but is also a substrate of uridine 5ʹ-diphospho (UDP)-glucuronosyltransferases (UGTs). The objective of this study was to build a physiologically based pharmacokinetic (PBPK) model comprising dabigatran etexilate, dabigatran, and dabigatran 1-O-acylglucuronide to describe the pharmacokinetics in healthy adults and renally impaired patients mechanistically.
Model development and evaluation were carried out using (i) physicochemical and absorption, distribution, metabolism, and excretion (ADME) parameter values of all three analytes; (ii) concentration–time profiles from 13 studies of healthy and renally impaired individuals after varying doses (0.1–300 mg), intravenous (dabigatran) and oral (dabigatran etexilate) administration, and different formulations of dabigatran etexilate (capsule, solution); and (iii) drug–drug interaction studies of dabigatran with the P-gp perpetrators rifampin (inducer) and clarithromycin (inhibitor).
A PBPK model of dabigatran was successfully developed. The predicted area under the plasma concentration–time curve, trough concentration, and half-life values of the assessed clinical studies satisfied the two-fold acceptance criterion. Metabolic clearances of dabigatran etexilate and dabigatran were implemented using data on carboxylesterase 1/2 enzymes and UGT subtype 2B15. In severe renal impairment, the UGT2B15 metabolism and the P-gp transport in the model were reduced to 67% and 65% of the rates in healthy adults.
This is the first implementation of a PBPK model for dabigatran to distinguish between the prodrug, active moiety, and main active metabolite. Following adjustment of the UGT2B15 metabolism and P-gp transport rates, the PBPK model accurately predicts the pharmacokinetics in renally impaired patients.
Compliance with Ethical Standards
This study was partly funded by Boehringer Ingelheim Pharma GmbH & Co. KG.
Conflict of interest
Daniel Moj worked as consultant for Boehringer Ingelheim Pharma GmbH & Co. KG. Hugo Maas and José David Gómez-Mantilla are employees of Boehringer Ingelheim Pharma GmbH & Co. KG. André Schaeftlein gave lectures for physicians hosted by Boehringer Ingelheim Pharma GmbH & Co. KG and received a research grant from Boehringer Ingelheim Pharma GmbH & Co. KG. Nina Hanke reported no conflict of interest. Thorsten Lehr received research grants from Boehringer Ingelheim Pharma GmbH & Co. KG.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the studies.
- 1.Boehringer Ingelheim Pharmaceuticals Inc. Full prescribing information: Pradaxa, 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s024lbl.pdf. Accessed 29 Oct 2018.
- 5.Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292–303. https://doi.org/10.1111/j.1365-2125.2007.02899.x.CrossRefGoogle Scholar
- 7.Boehringer Ingelheim Clinical Study Synopsis for Public Disclosure - BI Trial No. 1160.5. Tolerability of single rising doses of 0.1 mg, 1 mg, and 5 mg BIBR 953 ZW IV (placebo-controlled in each dose group; substudy 1) and absolute and relative bioavailability of 100 mg BIBR 1048 tablet and of solution and of 1 mg or 5 mg BIBR 953 ZW IV, 2001. https://trials.boehringer-ingelheim.com/public/trial_results_documents/1160/1160.5_U01-1807.pdf. Accessed 29 Oct 2018.
- 9.Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259–68. https://doi.org/10.2165/11318170-000000000-00000.CrossRefGoogle Scholar
- 10.Kooiman J, Van Der Hulle T, Maas H, Wiebe S, Formella S, Clemens A, et al. Pharmacokinetics and pharmacodynamics of dabigatran 75 mg b.i.d. in patients with severe chronic kidney disease. J Am Coll Cardiol 2016;67:2442–4. https://doi.org/10.1016/j.jacc.2016.03.516.
- 11.Prins MH, Lensing AWA, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11:21. https://doi.org/10.1186/1477-9560-11-21.CrossRefGoogle Scholar
- 12.Trocóniz IF, Tillmann C, Liesenfeld K-H, Schäfer H-G, Stangier J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol. 2007;47:371–82. https://doi.org/10.1177/0091270006297228.CrossRefGoogle Scholar
- 13.Liesenfeld K-H, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9:2168–75. https://doi.org/10.1111/j.1538-7836.2011.04498.x.CrossRefGoogle Scholar
- 14.Dansirikul C, Lehr T, Liesenfeld K-H, Haertter S, Staab a. A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery. Thromb Haemost 2012;107:775–85. https://doi.org/10.1160/TH11-09-0656.
- 16.Open Systems Pharmacology Suite manual, version 7.4. 2018. https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/master/Open-Systems-Pharmacology-Suite.pdf. Accessed 22 Feb 2019.
- 21.Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34:401–31. https://doi.org/10.1007/s10928-007-9053-5.CrossRefGoogle Scholar
- 26.Achour B, Russell MR, Barber J, Rostami-Hodjegan A. Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5’-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab Dispos. 2014;42:500–10. https://doi.org/10.1124/dmd.113.055632.CrossRefGoogle Scholar
- 28.Claassen K, Willmann S, Eissing T, Preusser T, Block M. A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine renin-angiotensin-aldosterone system. Front Physiol. 2013;4:4. https://doi.org/10.3389/fphys.2013.00004.CrossRefGoogle Scholar
- 29.Boehringer Ingelheim clinical study synopsis for public disclosure - BI trial no. 1160.61. Pharmacokinetics, safety and pharmacodynamics after multiple oral doses of dabigatran etexilate capsule (110 mg and 150 mg b.i.d., 7 days) in healthy Japanese and Caucasian male subjects (open label study), 2006. https://trials.boehringer-ingelheim.com/public/trial_results_documents/1160/1160.61_U06-3420.pdf. Accessed 29 Oct 2018.
- 30.Huang F, Wiebe S, Jungnik A, Gropper S, Brueckmann M, Hohl K, et al. Assessment of the relative bioavailability of dabigatran etexilate as pellets on food and as granules resolved in reconstitution solution, compared with dabigatran etexilate as hard capsules [poster no. 008]. Clin Pharmacokinet Pharmacodyn 2017;6 Suppl. 1. https://doi.org/10.1002/cpdd.385.
- 32.Boberg M, Vrana M, Mehrotra A, Pearce RE, Gaedigk A, Bhatt DK, et al. Age-dependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by LC-MS/MS proteomics: application to PBPK modeling of oseltamivir in vivo pharmacokinetics in infants. Drug Metab Dispos. 2017;45:216–23. https://doi.org/10.1124/dmd.116.072652.CrossRefGoogle Scholar
- 39.Naud J, Michaud J, Boisvert C, Desbiens K, Leblond F a, Mitchell A, et al. Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther 2006;320:978–85. https://doi.org/10.1124/jpet.106.112631.
- 40.Nolin TD, Naud J, Leblond F a, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 2008;83:898–903. https://doi.org/10.1038/clpt.2008.59.
- 41.Langenbucher F. Letters to the Editor: Linearization of dissolution rate curves by the Weibull distribution. J Pharm Pharmacol. 1972;24:979–81. https://doi.org/10.1111/j.2042-7158.1972.tb08930.x.CrossRefGoogle Scholar
- 42.Chu X, Liao M, Shen H, Yoshida K, Zur AA, Arya V, et al. Clinical probes and endogenous biomarkers as substrates for transporter drug-drug interaction evaluation: perspectives from the international transporter consortium. Clin Pharmacol Ther. 2018;104:836–64. https://doi.org/10.1002/cpt.1216.CrossRefGoogle Scholar
- 44.Milne R, Nation R, Somogyi A, Bochner F, Griggs W. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br J Clin Pharmacol. 1992;34:53–9. https://doi.org/10.1111/j.1365-2125.1992.tb04107.x.CrossRefGoogle Scholar
- 45.Varma MVS, Lin J, Bi Y, Kimoto E, Rodrigues AD. Quantitative rationalization of gemfibrozil drug interactions: consideration of transporters-enzyme interplay and the role of circulating metabolite gemfibrozil 1-O-β-glucuronide. Drug Metab Dispos. 2015;43:1108–18. https://doi.org/10.1124/dmd.115.064303.CrossRefGoogle Scholar
- 46.Sallustio BC, Fairchild BA, Pannall PR. Interaction of human serum albumin with the electrophilic metabolite 1-O-gemfibrozil-beta-D-glucuronide. Drug Metab Dispos. 1997;25:55–60.Google Scholar
- 53.Pauli-Magnus C, Hofmann U, Mikus G, Kuhlmann U, Mettang T. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 1999;14:903–9. https://doi.org/10.1093/ndt/14.4.903.CrossRefGoogle Scholar
- 55.Mutsaers HAM, Wilmer MJG, Reijnders D, Jansen J, van den Broek PHH, Forkink M, et al. Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration. Biochim Biophys Acta. 2013;1832:142–50. https://doi.org/10.1016/j.bbadis.2012.09.006.CrossRefGoogle Scholar
- 57.Sallustio BC, Purdie YJ, Birkett DJ, Meffin PJ. Effect of renal dysfunction on the individual components of the acyl-glucuronide futile cycle. J Pharmacol Exp Ther. 1989;251:288–94.Google Scholar
- 64.Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs. 2009;9:59–68. https://doi.org/10.2165/00129784-200909010-00006.CrossRefGoogle Scholar
- 66.Boehringer Ingelheim Clinical Study Synopsis for Public Disclosure - BI Trial No. 1160.81. Safety, tolerability and pharmacokinetics study after single and multiple oral doses of dabigatran etexilate capsule (110 mg, 150 mg b.i.d., 7 days) in healthy Chinese subjects (open label study), 2010. https://trials.boehringer-ingelheim.com/public/trial_results_documents/1160/1160.81_U10-3381-01.pdf. Accessed 29 Oct 2018.
- 67.Martin J, Esmaeili H, Manuel RC, Petrini M, Wiebe S, Maas H. A prospective, open label study to evaluate the pharmacokinetics of dabigatran in patients with non-valvular atrial fibrillation and severe renal impairment who are receiving dabigatran etexilate (75 mg twice daily). FASEB J 2017;31:674.9-674.9. https://doi.org/10.1096/fasebj.31.1_supplement.674.9.
- 69.Boehringer Ingelheim Pharmaceuticals Inc. Dabigatran Etexilate Capsules (75 mg, 110 mg, and 150 mg). Environmental Assessment, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512orig1s000ea.pdf. Accessed 29 Oct 2018.
- 70.U.S. Food and Drug Administration (FDA). Approval package for application number 22-512/S-011 (PRADAXA), 2012. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022512Orig1s011_replace.pdf. Accessed 29 Oct 2018.
- 72.Kishimoto W, Ishiguro N, Ludwig-Schwellinger E, Ebner T, Schaefer O. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold. Drug Metab Dispos. 2014;42:257–63. https://doi.org/10.1124/dmd.113.053769.CrossRefGoogle Scholar
- 73.Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, et al. PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil and digoxin. CPT Pharmacometrics Syst Pharmacol 2018. https://doi.org/10.1002/psp4.12343.
- 75.Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63:321–8. https://doi.org/10.1016/j.jacc.2013.07.104.CrossRefGoogle Scholar
- 76.ChemAxon. Marvin JS. https://www.chemaxon.com/products/marvin/marvin-js/. Accessed 18 Jan 2017